PSTV - Plus Therapeutics

-

$undefined

N/A

(N/A)

Plus Therapeutics NasdaqCM:PSTV Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests, such as the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.

Location: 2710 Reed Road, Houston, TX, 77051, United States | Website: https://plustherapeutics.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

6.901M

Cash

3.606M

Avg Qtr Burn

-2.639M

Short % of Float

13.00%

Insider Ownership

6.07%

Institutional Own.

7.50%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.